Harmless gut bacteria inject proteins straight into our cells

Introduction: the microbiome has a hidden syringe

An unsuspected molecular conversation

For decades, we pictured the gut microbiome as a peaceful mass of bacteria, confined to digestion and a few favors rendered in exchange for room and board. That image just shattered. Researchers have discovered that many common, non-pathogenic gut bacteria carry tiny syringe-shaped structures capable of injecting proteins directly into our cells. A mechanism once thought to be the exclusive property of dangerous microbes has just been spotted in perfectly ordinary residents of our digestive tract, the very same bacteria found in the microbiome of any healthy person.

This discovery, published in March 2026 by a team from Helmholtz Munich, working with Ludwig Maximilian University, Aix-Marseille University, and Inserm, upends what we thought we knew about the communication between the microbiome and the human body. This is no longer a simple, passive cohabitation: it is an active, ongoing molecular exchange, far more sophisticated than anyone imagined. The sheer fact that such an international team took on this question underscores how much is at stake scientifically.

The syringe system, once reserved for the bad guys

The structure in question is called a type III secretion system. It was mostly known in feared pathogenic bacteria, such as salmonella, which use it to inject their own proteins — called effector proteins — directly into the cells they infect, hijacking their machinery for their own benefit. This tiny biological device acts literally like a microscopic syringe, capable of piercing a human cell's membrane to deposit its contents with remarkable precision, without destroying the targeted cell.

What the researchers showed is that this same tool is not the exclusive property of dangerous microbes. Many commensal bacteria — the ones that normally live in our intestines without making us sick — are equipped with it too. This is an important conceptual shift: the weapon we thought was typical of infections actually serves, in friendly bacteria, as a daily molecular dialogue with our own cells, almost as if our microscopic roommates were constantly sending little chemical messages to our body.

How this protein injection actually works

More than a thousand interactions mapped

To understand the scale of the phenomenon, the team led by Professor Pascal Falter-Braun, director of the Institute of Network Biology at Helmholtz Munich, mapped the possible exchanges between bacterial proteins and human proteins. The result: more than a thousand interactions were identified between effector proteins from gut bacteria and proteins present in our cells. That is a molecular communication network of a scale nobody suspected until now, far denser than earlier models had suggested.

The study's lead authors, Veronika Young and Bushra Dohai, found that these effector proteins primarily target two major biological domains: immune system regulation and metabolism. In other words, these bacteria do not simply coexist alongside our cells — they actively help shape how our body responds to outside threats and manages its daily energy needs, a far more active role than the one previously assigned to them.

A direct influence on key immune pathways

Researchers found that some of these injected proteins interact with major immune signaling mechanisms, notably the NF-κB pathway and cytokine responses, those chemical messengers that orchestrate inflammation throughout the body. One striking example involves TNF (tumor necrosis factor), a cytokine whose blockade already forms a standard treatment for certain chronic inflammatory diseases. The fact that gut bacteria interact directly with these pathways suggests they actively participate in the balance — or imbalance — of our immune system, far beyond the simple digestive role once attributed to them.

This direct influence changes how scientists view the role of the microbiome. It is no longer just a matter of bacteria producing beneficial or harmful metabolites indirectly: some intervene with surgical precision, injecting proteins that slot directly into our own cell-signaling cascades, a bit like a message inserted straight into the wiring of our immune system.

The link to Crohn's disease and inflammatory conditions

These genes show up more often in Crohn's patients

One of the most significant findings of this research concerns Crohn's disease, a chronic inflammatory bowel condition classified among autoimmune diseases. Researchers observed that the genes responsible for producing these bacterial effector proteins are more common in the gut microbiomes of people with this disease than in those of healthy people. This observation suggests that a direct transfer of bacterial proteins into human cells could help sustain chronic intestinal inflammation, a mechanism that was completely absent from the classic explanations of the disease until now.

This is a lead, not yet a settled fact. But it opens a new avenue for understanding why certain inflammatory bowel diseases resist treatment or evolve so unpredictably from one patient to another. If each person's microbiome carries a different arsenal of these injection systems, that could explain part of the clinical variability seen in how the disease progresses, a factor that largely escaped earlier models.

A path toward rethinking future treatments

Understanding precisely which bacterial proteins interact with which human targets could eventually pave the way for more targeted treatments. Rather than trying to wipe out entire swaths of the microbiome — a blunt approach that is often counterproductive for overall gut health — researchers are considering the possibility of specifically neutralizing the problematic interactions while preserving the benefits these same bacteria otherwise bring to the body.

This precision approach would fit with the broader evolution of microbiome medicine, which increasingly seeks to separate beneficial mechanisms from harmful ones within a single bacterial community, rather than judging the whole group as one, as was common just a decade ago.

Why this discovery is shaking up microbiology

A blurring line between commensal and pathogen

Until now, microbiology textbooks drew a fairly sharp line between pathogenic bacteria, equipped with a sophisticated arsenal for infection, and commensal bacteria, considered relatively passive at the molecular level. This study blurs that historic boundary. The mere fact that a bacterium does not cause disease does not mean it stays inactive at the molecular level — it can instead carry on an intense, continuous biochemical conversation with our cells, every day, without us ever being aware of it.

This conceptual revision has implications that go well beyond Crohn's disease alone. If bacteria considered harmless actively intervene in immune and metabolic regulation, then our entire understanding of the host-microbiome dialogue needs to be revised in light of these new molecular tools, a scientific undertaking that is only just beginning.

A field of research still largely unexplored

The study's authors stress that this mapping work is only a start. With more than a thousand interactions already identified between bacterial and human proteins, there are probably hundreds, if not thousands, more exchanges waiting to be discovered in the coming years. Each new interaction could potentially reveal a previously unsuspected mechanism, whether in inflammation regulation, digestion, or even physiological functions not yet identified at all.

This kind of research also illustrates the value of international collaboration: it was by combining the expertise of several European institutions — German and French among them — that researchers managed to carry out mapping of this scale, an exercise that would have been difficult for any single, isolated laboratory working alone.

What this changes about how we see the human body

An organism shaped by billions of invisible partners

Our intestine is home to tens of trillions of bacteria, a number that is dizzying and far exceeds the number of cells that make up our own body. For a long time, this mass was seen as a simple fermentation ecosystem, useful for digesting fiber and synthesizing certain vitamins. The discovery of a type III secretion system in commensal bacteria forces a deep revision of that view: our digestive tract is in reality a crossroads of biochemical exchange of staggering density, where each bacterial species can potentially modulate specific physiological functions.

This conceptual revision fits into a broader movement in biomedical research, which over the past decade has increasingly come to treat the microbiome as an organ in its own right, capable of interacting with the brain, the immune system, and even the body's overall energy metabolism. Adding this direct protein-injection mechanism reinforces the idea of a microbiome that is an active player, not a mere spectator, in our health.

Implications that reach beyond the gut alone

If commensal bacteria can inject proteins capable of influencing immune pathways as central as NF-κB, it becomes reasonable to ask whether similar effects might be observed in other inflammatory diseases, beyond Crohn's disease alone. Some researchers are already floating the possibility of exploring this mechanism in the context of metabolic diseases, or even certain autoimmune conditions affecting organs far removed from the gut.

This lead obviously still needs confirmation through further studies, but it illustrates the potential reach of the discovery well: a molecular mechanism discovered in the gut could, in time, shed light on phenomena observed elsewhere in the human body.

Conclusion: our gut, an unrecognized molecular crossroads

What this discovery actually changes

This research is a reminder that the gut microbiome is not a mere bystander in our biology, but a full molecular player capable of acting directly on our cells through mechanisms of remarkable precision. Bacteria long considered harmless are using a tool once thought reserved for infectious agents, to converse with our immune system and metabolism, with potential consequences for diseases like Crohn's disease.

The coming years of research should help clarify which of these interactions are beneficial, which are neutral, and which could one day become therapeutic targets. In the meantime, this discovery calls for a certain humility: our body hosts molecular communication mechanisms that science is only now beginning to decode, after decades spent ignoring their very existence.

A more precise future for microbiome medicine

As scientists refine this map of interactions between bacteria and human cells, we can hope to see the emergence of far more targeted treatments for inflammatory bowel diseases, capable of precisely neutralizing harmful mechanisms without destroying the overall balance of the microbiome. A prospect that, just a few years ago, sounded almost like science fiction, and today rests on published, verifiable data.

By Maxime Marquette, columnist

Sources

Primary sources

Helmholtz Munich — Newsroom, press release on the discovery of type III secretion systems in commensal bacteria — 2026

ScienceDaily — Scientists find gut bacteria inject proteins that control your immune system — March 2026

Nature — Subject page Microbiome, reference resources and publications on the microbiome — 2026

Secondary sources

Futura-Sciences — Health section, science news on the microbiome and immunity — 2026

Sciences et Avenir — Health section, French science coverage — 2026

Pour la Science — Reference science magazine, biology and medicine news — 2026